
Sionna Therapeutics Inc SION.O:
SIONNA THERAPEUTICS ANNOUNCES POSITIVE PHASE 1 DATA FOR NBD1 STABILIZERS SION-719 AND SION-451 AND ADVANCES BOTH PROGRAMS IN CLINICAL DEVELOPMENT FOR CYSTIC FIBROSIS
SIONNA THERAPEUTICS INC -NEXT TRIALS TO INITIATE IN SECOND HALF OF 2025 WITH TOPLINE DATA EXPECTED IN MID-2026
SIONNA THERAPEUTICS- SION-719 AND SION-451 WERE GENERALLY WELL TOLERATED AND ACHIEVED DESIRED PHARMACOKINETIC TARGETS